Lucid Diagnostics Inc. (LUCD) Research

Lucid Diagnostics Inc. is a commercial-stage medical technology firm focused on diagnostic solutions. The company's primary objective is to serve patients afflicted with gastroesophageal reflux disease (GERD), commonly referred to as chronic heartburn or acid reflux, especially those at increased risk of developing precancerous esophageal conditions or the particularly aggressive esophageal adenocarcinoma. Their key product offerings include EsoGuard, an internally developed esophageal DNA test, and EsoCheck, a specialized device designed for collecting esophageal cells. Formed in 2018, Lucid Diagnostics Inc. has its headquarters in New York, New York, and operates as a subsidiary of PAVmed Inc.

Market snapshot

Symbol
LUCD
Price
$1.08
Day change
+9.90%
Market cap
$110.5M
P/E ratio
-2.45x
52-week range
0.9-1.629
Sector
Healthcare
Industry
Medical - Devices
Next earnings
in 2 months
Analyst price target
$2.00

Peer companies

  • Apyx Medical Corporation (APYX)
  • Anteris Technologies Global Corp. (AVR)
  • Opus Genetics, Inc. (IRD)
  • Incannex Healthcare Limited (IXHL)
  • Owlet, Inc. (OWLT)
  • AVITA Medical, Inc. (RCEL)
  • Rapid Micro Biosystems, Inc. (RPID)
  • Scilex Holding Company (SCLX)

Recent insider activity

  • Matheis Dennis — P-Purchase (245000 shares) on 2026-05-20
  • Lee Victoria Tou-ho — trade (100000 shares) on 2026-03-23
  • Lee Victoria Tou-ho — trade (0 shares) on 2026-03-23
  • Aklog Lishan — A-Award (2170000 shares) on 2026-02-20
  • Matheis Dennis — A-Award (123000 shares) on 2026-02-20

Open Lucid Diagnostics Inc. (LUCD) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.